Quantcast

Latest HER2-positive breast cancer Stories

2014-10-22 23:06:39

RnRMarketResearch.com adds “Perjeta & Kadcyla (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023” to its store. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market. Dallas, Texas (PRWEB) October 22, 2014 "Perjeta (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023" HER2-positive breast cancer is the second most common cancer in...

2014-10-22 08:30:21

DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports for United States (US), China and Japan to the cancer drugs market research collection of its online library. The PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023...

2013-12-11 12:07:24

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "Worldwide, anthracyclines such as doxorubicin [Adriamycin] and epirubicin have...

2013-12-11 12:05:10

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "We have previously shown that high levels of tumor-infiltrating lymphocytes [immune cells in a tumor] are predictive of response to trastuzumab and chemotherapy administered after surgery for early-stage,...

2012-10-08 13:27:11

The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of the National Cancer Institute. Breast cancer is one of the most common causes of cancer deaths in the U.S. with approximately 39,520 women succumbing to the disease in 2011. HER2-postive breast cancer is known to be more aggressive and less responsive to treatments compared...

2012-02-13 23:03:47

Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. Researchers are therefore seeking ways to enhance the effectiveness of trastuzumab. In this context, a team of researchers led by Ronald Levy, at Stanford University, Stanford, has identified a sequential treatment regimen that enhances the effectivenss of trastuzumab in...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.